These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38315389)

  • 21. Absence of Either Ripk3 or Mlkl Reduces Incidence of Hepatocellular Carcinoma Independent of Liver Fibrosis.
    Mohammed S; Thadathil N; Ohene-Marfo P; Tran AL; Van Der Veldt M; Georgescu C; Oh S; Nicklas EH; Wang D; Haritha NH; Luo W; Janknecht R; Miller BF; Wren JD; Freeman WM; Deepa SS
    Mol Cancer Res; 2023 Sep; 21(9):933-946. PubMed ID: 37204757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new NASH model in aged mice with rapid progression of steatohepatitis and fibrosis.
    Li X; Lu Y; Liang X; Zhou X; Li D; Zhang Z; Niu Y; Liu S; Ye L; Zhang R
    PLoS One; 2023; 18(5):e0286257. PubMed ID: 37228085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experimental non-alcoholic steatohepatitis in Göttingen Minipigs: consequences of high fat-fructose-cholesterol diet and diabetes.
    Schumacher-Petersen C; Christoffersen BØ; Kirk RK; Ludvigsen TP; Zois NE; Pedersen HD; Vyberg M; Olsen LH
    J Transl Med; 2019 Apr; 17(1):110. PubMed ID: 30943987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet.
    Ganguly S; Muench GA; Shang L; Rosenthal SB; Rahman G; Wang R; Wang Y; Kwon HC; Diomino AM; Kisseleva T; Soorosh P; Hosseini M; Knight R; Schnabl B; Brenner DA; Dhar D
    Cell Mol Gastroenterol Hepatol; 2021; 12(3):891-920. PubMed ID: 34062281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Branched-chain amino acids prevent hepatic fibrosis and development of hepatocellular carcinoma in a non-alcoholic steatohepatitis mouse model.
    Takegoshi K; Honda M; Okada H; Takabatake R; Matsuzawa-Nagata N; Campbell JS; Nishikawa M; Shimakami T; Shirasaki T; Sakai Y; Yamashita T; Takamura T; Tanaka T; Kaneko S
    Oncotarget; 2017 Mar; 8(11):18191-18205. PubMed ID: 28212548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.
    Van Campenhout S; Tilleman L; Lefere S; Vandierendonck A; Raevens S; Verhelst X; Geerts A; Van Nieuwerburgh F; Van Vlierberghe H; Devisscher L
    Metabolism; 2020 Jun; 107():154220. PubMed ID: 32243868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis.
    Kimura T; Tanaka N; Fujimori N; Sugiura A; Yamazaki T; Joshita S; Komatsu M; Umemura T; Matsumoto A; Tanaka E
    World J Gastroenterol; 2018 Apr; 24(13):1440-1450. PubMed ID: 29632425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle.
    Dowman JK; Hopkins LJ; Reynolds GM; Nikolaou N; Armstrong MJ; Shaw JC; Houlihan DD; Lalor PF; Tomlinson JW; Hübscher SG; Newsome PN
    Am J Pathol; 2014 May; 184(5):1550-61. PubMed ID: 24650559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oxymatrine alleviates high-fat diet/streptozotocin-induced non-alcoholic fatty liver disease in C57BL/6 J mice by modulating oxidative stress, inflammation and fibrosis.
    Lou D; Fang Q; He Y; Ma R; Wang X; Li H; Qi M
    Biomed Pharmacother; 2024 May; 174():116491. PubMed ID: 38537582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eicosapentaenoic acid attenuates obesity-related hepatocellular carcinogenesis.
    Inoue-Yamauchi A; Itagaki H; Oda H
    Carcinogenesis; 2018 Jan; 39(1):28-35. PubMed ID: 29040439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peretinoin, an acyclic retinoid, suppresses steatohepatitis and tumorigenesis by activating autophagy in mice fed an atherogenic high-fat diet.
    Okada H; Takabatake R; Honda M; Takegoshi K; Yamashita T; Nakamura M; Shirasaki T; Sakai Y; Shimakami T; Nagata N; Takamura T; Tanaka T; Kaneko S
    Oncotarget; 2017 Jun; 8(25):39978-39993. PubMed ID: 28591717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model.
    Orime K; Shirakawa J; Togashi Y; Tajima K; Inoue H; Nagashima Y; Terauchi Y
    Eur J Pharmacol; 2016 Feb; 772():22-32. PubMed ID: 26724391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer.
    Asgharpour A; Cazanave SC; Pacana T; Seneshaw M; Vincent R; Banini BA; Kumar DP; Daita K; Min HK; Mirshahi F; Bedossa P; Sun X; Hoshida Y; Koduru SV; Contaifer D; Warncke UO; Wijesinghe DS; Sanyal AJ
    J Hepatol; 2016 Sep; 65(3):579-88. PubMed ID: 27261415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNA-223 Ameliorates Nonalcoholic Steatohepatitis and Cancer by Targeting Multiple Inflammatory and Oncogenic Genes in Hepatocytes.
    He Y; Hwang S; Cai Y; Kim SJ; Xu M; Yang D; Guillot A; Feng D; Seo W; Hou X; Gao B
    Hepatology; 2019 Oct; 70(4):1150-1167. PubMed ID: 30964207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lessons from mouse models of high-fat diet-induced NAFLD.
    Nakamura A; Terauchi Y
    Int J Mol Sci; 2013 Oct; 14(11):21240-57. PubMed ID: 24284392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Portosystemic shunting prevents hepatocellular carcinoma in non-alcoholic fatty liver disease mouse models.
    Peloso A; Lacotte S; Gex Q; Slits F; Moeckli B; Oldani G; Tihy M; Hautefort A; Kwak B; Rubbia-Brandt L; Toso C
    PLoS One; 2023; 18(12):e0296265. PubMed ID: 38157359
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosis.
    Sakuma T; Nakamura M; Chiba T; Iwanaga T; Kan M; Kojima R; Ao J; Ma Y; Unozawa H; Fujita N; Kanayama K; Kanzaki H; Koroki K; Kobayashi K; Nakagawa R; Kanogawa N; Kiyono S; Kondo T; Saito T; Ogasawara S; Nakamoto S; Muroyama R; Kato J; Kishimoto T; Kato N
    Lab Invest; 2022 Oct; 102(10):1150-1157. PubMed ID: 35643859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AIM-deficient mouse fed a high-trans fat, high-cholesterol diet: a new animal model for nonalcoholic fatty liver disease.
    Komatsu G; Nonomura T; Sasaki M; Ishida Y; Arai S; Miyazaki T
    Exp Anim; 2019 May; 68(2):147-158. PubMed ID: 30487357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxidative stress and Liver X Receptor agonist induce hepatocellular carcinoma in Non-alcoholic steatohepatitis model.
    Shimizu Y; Tamura T; Kemmochi A; Owada Y; Ozawa Y; Hisakura K; Matsuzaka T; Shimano H; Nakano N; Sakashita S; Oda T; Ohkohchi N
    J Gastroenterol Hepatol; 2021 Mar; 36(3):800-810. PubMed ID: 32870526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.
    Sun G; Jackson CV; Zimmerman K; Zhang LK; Finnearty CM; Sandusky GE; Zhang G; Peterson RG; Wang YJ
    BMC Gastroenterol; 2019 Mar; 19(1):41. PubMed ID: 30885145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.